Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Take Five: A shot in the arm

Published 11/13/2020, 08:27 AM
Updated 11/13/2020, 08:30 AM
© Reuters. The spread of the coronavirus disease (COVID-19) in New York

(Reuters) - 1/ RECOVERY ALPHABET SOUP

The world economic outlook is suddenly a little bit brighter after upbeat news on the Pfizer (NYSE:PFE) COVID-19 vaccine.

Hopes of a strong "V" or even a "U" -shaped recovery faded after a second wave of infections forced major economies to lock down again, setting them up for a double-dip "W" growth path.

Upcoming readings on Chinese and U.S. industrial output will show whether a speedy economic rebound is still possible. But even if a vaccine rollout happens sooner than expected, pandemic damage won't be easily undone. W, V, or whatever the shape of recovery, central bank stimulus will stay in place.

(GRAPHIC - W-shape recovery?: https://graphics.reuters.com/HEALTH-CORONAVIRUS/yxmpjeomovr/chart.png)

2/ ROLL UP FOR BONDS

After months of slumber, U.S. Treasury yields have sprung to life and Wednesday's record-sized auction may show which way they might head.

Pfizer's encouraging update on its COVID-19 vaccine sent 10-year borrowing costs to the highest since March and drove the yield curve to its steepest in more than two years. Those moves have since been offset by the resurgent coronavirus and doubts the Federal Reserve will permit yields to rise too far.

Demand at the Treasury's Nov 12 sale of $27 billion in 30-year bonds was below this year's average. Unexceptional results at the upcoming $27 billion in 20-year bonds could become another factor pushing yields higher.

(GRAPHIC - Yields on longer-dated Treasury debt: https://fingfx.thomsonreuters.com/gfx/mkt/xlbpgzgdzvq/yields.png)

3/ STAND AND DELIVER

Just some days back, the lira slump was threatening to propel Turkey into full-blown crisis but a change of finance minister and central bank governor later and the currency has enjoyed its best week in nearly two decades.

On Thursday Nov 19, the central bank must show that its policymaking really has changed as much as President Tayyip Erdogan's recent moves suggest. What it means is that new central bank chief Naci Agbal has no choice but to deliver what markets want -- a 400-575 basis points interest rate hike.

Anything below 350 may seen as a cop-out. More importantly, any rate hike needs to stick -- and for that investors need to see proof Erdogan has overcome his oft-stated hostility to high borrowing costs.

(GRAPHIC - Turkey's lira and bonds have found hope: https://fingfx.thomsonreuters.com/gfx/mkt/bdwvklarypm/Pasted%20image%201605261542532.png)

4/ RED LINES IN CHINA DEBT

Bubbling fears of debt defaults in the Chinese public sector are tempering some of the euphoria felt towards Chinese markets after the U.S. election.

With debt running at three times annual GDP, this market is prone to letting off steam. This time, as monetary reins tighten and the pandemic impact starts to show, companies such as property developer Evergrande (HK:3333) and BMW's state-backed parent Huachen Automotive Group are in the crosshairs.

China's new 'three red lines' indebtedness rules may to a degree help alleviate solvency concerns. But the latest jitters and the extent of government support may give pause to investors thronging to the world's second-biggest bond market.

(GRAPHIC - China's debt pile: https://fingfx.thomsonreuters.com/gfx/mkt/xklpybgbovg/Pasted%20image%201605196373053.png)

5/ LAST SHALL BE FIRST

The summertime easing of lockdown restrictions allowed a chunk of European and U.S. companies to post better-than-expected Q3 earnings but U.S. hegemony remains in place.

European companies are expected to report a 23.8% year-on-year decline in Q3 earnings, compared to 50.8% tumble in Q2, according to Refinitiv I/B/E/S data. But the U.S. Q3 profit drop is expected at just 7.8%.

That's because of the larger European exposure to cyclical sectors such as travel or luxury or banks, which are more closely tied to the state of the economy.

The upside is that a credible vaccine could help Europe Inc roar ahead. Indeed, recent vaccine news induced investors to up forecasts for Europe to 30% for the first 2021 quarter -- double the S&P500's rate.

© Reuters. The spread of the coronavirus disease (COVID-19) in New York

(GRAPHIC - Europe vs U.S. earnings: https://fingfx.thomsonreuters.com/gfx/buzz/jznpnnbnbpl/Pasted%20image%201605194984681.png)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.